CorMedix (CRMD) announced that DefenCath has received an Innovative Technology designation from Vizient.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRMD:
- CorMedix price target raised to $22 from $21 at RBC Capital
- Cormedix’s Strong Financial Performance and Promising Prospects Drive Buy Rating
- Midday Fly By: AWS hit by outage, Kering sells beauty unit
- Morning Movers: Cleveland-Cliffs surges following earnings report
- CorMedix upgraded to Buy from Hold at D. Boral Capital